Genmab A/S filings document the company’s reporting as a foreign private issuer and its formal company announcements on antibody-medicine operations, financial results, governance and share capital. Recent Form 6-K reports include interim financial information, DARZALEX® royalty-related sales disclosures from Johnson & Johnson, pipeline commentary for EPKINLY®, Rina-S® and petosemtamab, and updates incorporated by reference into Form S-8 registration statements.
The filing record also documents Danish-market disclosure matters, including major shareholder notifications, managerial transactions in shares and linked securities, amendments to the articles of association, and registered share capital reductions. These filings provide the formal record for Genmab’s capital structure, ownership notifications, governance documents and recurring biotechnology business disclosures.
Genmab A/S has furnished a Form 6-K for March 2026, primarily to submit its updated Articles of Association as Exhibit 3.1. The filing states that this report will be incorporated by reference into several existing Genmab Form S-8 registration statements and will form part of those documents from the filing date.
Genmab A/S filed a Form 6-K to share a company announcement correcting the reported price for recent insider equity awards. A prior notice had shown a share price of DKK 0.00 for transactions involving managerial employees and related persons; the correct price is DKK 1,867.50 per share.
The correction covers acquisitions of Genmab shares due to vesting of restricted stock units granted on February 24, 2023 to President & CEO Jan van de Winkel, EVP & CFO Anthony Pagano, and board members Mijke Zachariasse, Martin Schultz, and Michael Kavanagh. All transactions occurred outside the market and reflect routine equity compensation vesting rather than open-market trading.
Genmab A/S provides an update on its ongoing share buy-back program, which was initiated to repurchase up to 342,130 shares for a maximum of DKK 725 million to honor commitments under its Restricted Stock Unit program.
From February 23 to 27, 2026, Genmab repurchased 18,000, 12,000, 15,000, 20,000 and 20,000 shares on successive trading days, at average prices between DKK 1,825.23 and DKK 1,856.49, for total consideration of DKK 156,630,920 during this period and DKK 271,855,470 accumulated under the program. Following these transactions, Genmab holds 2,763,851 treasury shares, equal to 4.30% of its total share capital and voting rights.
Genmab A/S filed a Form 6-K detailing new equity compensation grants and related insider transaction disclosures. The board granted 587,495 restricted stock units to management and employees and 455,004 warrants to employees of Genmab and its subsidiaries.
Each restricted stock unit is granted cost-free, represents a conditional right to one Genmab share of nominal DKK 1, and has a fair value equal to the grant-date closing share price of DKK 1,848.50. These RSUs generally vest three years after grant, with executive management awards linked to forward-looking performance criteria.
The warrants are also granted cost-free, have an exercise price of DKK 1,848.50 per share, a calculated fair value of DKK 594.08 using the Black-Scholes formula, vest after three years and expire seven years from grant. The filing also itemizes grants to key individuals, including CEO Jan G. J. van de Winkel and CFO Anthony Pagano, under market abuse regulation disclosure rules.
Genmab A/S filed a Form 6-K as a foreign private issuer for February 2026. The report primarily furnishes an updated corporate document, listing the company’s Articles of Association as Exhibit 3.1. The filing is also incorporated by reference into several existing Genmab Form S-8 registration statements.
Genmab A/S is making a small share capital increase after employees exercised warrants, issuing 12,313 new shares. The new shares were subscribed for cash at various prices between DKK 1,147.50 and DKK 1,615.00 per share, generating approximately DKK 17.1 million in proceeds for the company.
The new shares equal about 0.02% of Genmab’s existing share capital and carry the same rights as existing ordinary shares, including voting and dividend rights from subscription. After this increase, the total nominal share capital is DKK 64,250,721, corresponding to 64,250,721 shares and votes, and the new shares are expected to be listed on Nasdaq Copenhagen following registration.
Genmab A/S provides an update on its recently initiated share buy-back program. The company plans to repurchase up to 342,130 shares with a maximum aggregate value of DKK 725 million to meet obligations under its Restricted Stock Unit program, with completion expected by March 31, 2026.
From February 18 to February 20, 2026, Genmab repurchased 23,000, 25,000 and 15,000 shares, respectively, for a total consideration of DKK 115,224,550. Following these transactions, Genmab holds 2,678,851 treasury shares, representing 4.17% of its total share capital and voting rights.
Genmab A/S filed a Form 6-K reporting insider share trading by its Executive Vice President & Chief Financial Officer, Anthony Pagano. On February 19, 2026, he executed a sale of 1,100 Genmab shares on Nasdaq Copenhagen at an aggregated price of DKK 1,810.10 per share. Individual trades were carried out at prices between DKK 1,810.00 and DKK 1,811.00. The disclosure is made under Article 19 of the EU Market Abuse Regulation and covers trading by a person discharging managerial responsibilities.
Genmab A/S is convening its Annual General Meeting on March 19, 2026 in Copenhagen and outlining key proposals for shareholder approval. Shareholders will be asked to adopt the audited 2025 Annual Report, grant discharge to the Board and Executive Management, and carry forward the profit of USD 963 million to retained earnings rather than paying a dividend.
The agenda includes an advisory vote on the 2025 Compensation Report, re-election of six directors, and re-appointment of Deloitte as auditor, including a limited assurance engagement on sustainability statements. Board and committee fees for 2026 are proposed to remain at 2025 levels, with a base fee of DKK 600,000 and specified supplements for chair, deputy chair and committee roles, plus restricted stock units under the remuneration policy.
Genmab’s Board also proposes a share capital reduction by nominally DKK 1,900,000 through cancellation of 1,900,000 treasury shares that were repurchased for a total of DKK 2,473,734,807.58, at an average price of DKK 1,301.97 per share. Following this, the Articles of Association would be amended to reflect the reduced share capital, which is currently DKK 64,238,408 divided into shares of DKK 1 each, with one vote per share.
Genmab A/S is launching a share buy-back program of up to 342,130 shares with a maximum total value of 725 million DKK. The program is designed to meet obligations under the company’s Restricted Stock Unit program and will run from February 18, 2026, and is expected to end no later than March 31, 2026, unless suspended or terminated.
Genmab has given a non-discretionary mandate to Danske Bank, which will independently execute purchases on Nasdaq Copenhagen and multilateral trading facilities under EU market abuse and Safe Harbour rules. As of February 17, 2026, Genmab holds 2,615,851 treasury shares, equal to 4.07% of its share capital.